OncoMed Pharma (OMED) Reports In-Line Q3 EPS

November 1, 2016 5:17 PM EDT
Get Alerts OMED Hot Sheet
Trade OMED Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

OncoMed Pharma (NASDAQ: OMED) reported Q3 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $9.48 million.

Cash, cash equivalents and short-term investments totaled $207.6 million as of September 30, 2016, compared to $171.5 million as of June 30, 2016. The company’s cash balance includes net proceeds of $59.2 million from a follow-on offering completed August 23, 2016.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment